Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7366 to 7380 of 7687 results

  1. Health technology evaluations: interim methods and process guide for the proportionate approach to technology appraisals (PMG40)

    This interim methods and process guide for the proportionate approach to technology appraisals has been incorporated into NICE health technology evaluations: the manual.

  2. Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal) (TA700)

    This guidance has been updated and replaced by NICE technology appraisal guidance 970 and NICE technology appraisal guidance 974.  

    Technology appraisal guidance
    Published
    19 May 2021

  3. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    In development [GID-TA11253] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

    In development [GID-TA11455] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]

    In development [GID-TA11001] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

    Technology appraisal guidance
    Published
    28 May 2003

  7. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]

    In development [GID-TA11302] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]

    In development [GID-TA11007] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)

    This guidance has been updated and replaced by NICE technology appraisal guidance 984.

    Technology appraisal guidance
    Published
    12 May 2021

  10. Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

    In development [GID-TA11166] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    In development [GID-TA11089] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007

    In development [GID-TA11567] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development [GID-TA10745] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development

  14. Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]

    In development [GID-TA11411] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]

    In development [GID-TA11165] Expected publication date: TBC

    Technology appraisal guidance
    In development